HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is Anti-Acne illuMask Legit? ERSP Finds That Company’s Claims Are

This article was originally published in The Rose Sheet

Executive Summary

There has been much buzz about the rise of beauty devices in recent years, but also skepticism about the products’ effectiveness and the legitimacy of associated claims. In its latest review of a home-use acne-treatment device – La Lumiere’s illuMask – the Electronic Retailing Self-Regulatory Program finds the firm’s performance claims adequately substantiated, consistent with previous device decisions.

You may also be interested in...



FDA’s Cannabidiol Crackdown: What Do Warning Letters Say About CBD In Cosmetics?

Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.

US House Cosmetics Hearing: Preemption, FDA Ingredient Review Could Be Regulatory Reform Snags

Federal preemption of state and local requirements that differ from federal mandates came up repeatedly at the House Energy & Commerce Health Subcommittee’s 4 December cosmetics hearing. Meanwhile, both NGO and industry stakeholders generally support FDA review of cosmetic ingredients, but the details of such a framework likely will be contentious as work progresses.

House Energy & Commerce Chair Pallone Highlights Proposed Reform Bills Ahead Of Cosmetics Hearing

House Energy & Commerce Committee Chairman Frank Pallone underscores FDA’s lack of resources and insufficient “regulatory tools” in a memo to Health Subcommittee members going into a 4 December hearing on cosmetics safety issues. The committee’s last hearing on the subject was in 2012 when Pallone unveiled the first version of his Cosmetics Safety Enhancement Act.

UsernamePublicRestriction

Register

RS019495

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel